Needs of people with rare diseases that can be supported by electronic resources: a scoping review

Janet C Long,1 Stephanie Best,1,2 Bróna Nic Giolla Easpaig,1,3 Sarah Hatem,1 Zoe Fehlberg,1,3 John Christodoulou,4,5 Jeffrey Braithwaite1

To cite: Long JC, Best S, Nic Giolla Easpaig B, et al. Needs of people with rare diseases that can be supported by electronic resources: a scoping review. BMJ Open 2022;12:e060394. doi:10.1136/bmjopen-2021-060394

ABSTRACT

Objectives Rare diseases are characterised by low incidence, often with little evidence for effective treatments. Isolated patients and specialist centres for rare diseases are increasingly connected, thanks to the internet. This scoping review aimed to identify issues facing people with a rare disease that authors report may be addressed by electronic resources (mobile applications, websites, social media platforms, telehealth and online portals).

Design Scoping review guided by the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines.

Data sources Medline, Embase and PsycInfo were searched, supplemented by hand searches of selected journals, in July 2021.

Eligibility criteria Peer-reviewed literature in English was searched using terms for rare disease (incidence <1:2000), electronic modalities (eg, mobile phone) and patient support terms. No date limit was set. Conference abstracts were included.

Data extraction and synthesis Data extracted: rare disease/group of diseases, name of the e-resource, need identified in the patient cohort, features of the e-resource, any other findings or observations of interest. From this, a framework was developed synthesising features across diseases and resources.

Results Seventy-two papers were found (from 383). Fifty-six electronic resources were described in 64 papers, while 12 papers were exploratory studies. Cystic fibrosis (n=28) was the most frequently addressed, followed by haemophilia (n=16).

Four domains and 23 subdomains of needs were extracted from the papers. The domains of needs were: support for self-management, access to high-quality information, access to appropriate specialist services, and social support. Subdomains are sometimes related to needs of individual rare diseases (eg, social isolation due to infection risk in people with cystic fibrosis). Fifteen electronic resources were identified that supported parents of children with rare disorders.

Conclusions While it can be argued that rare diseases, per se, may be no less distressing or onerous to care for than a high prevalence disease, rare diseases have unique features: the lengthy odyssey to find a diagnosis, then appropriate specialists, the lack of evidence around effective treatments, guidelines or access to knowledgeable general health service providers.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Individual named rare diseases/groups of diseases were included in the search terms to overcome deficiencies of searching only using ‘rare diseases’, but could not cover all rare diseases.

⇒ There are estimated to be 6–7000 rare diseases so searching by name (plus their synonyms) was not feasible.

⇒ Data extraction considered the type of electronic resource proposed, by disease and by the need of resource addressed.

⇒ Electronic resources were categorised into mobile applications, social support platforms, telehealth tools and online portals, and active (containing interactive content, eg, quizzes) and passive websites (information only).

INTRODUCTION

There are estimated 6–7000 different types of rare disease, many of them are genetic.1 We define a rare disease as a condition that has an incidence of less than 1 per 2000 live births in the population.1 Examples of rare diseases are fragile X syndrome, haemophilia A, osteogenesis imperfecta, cystic fibrosis, spinal muscular atrophy type 1 and neurofibromatosis type 2. The low incidence of rare diseases mean that specifics of individual diseases are not covered in medical education programmes which must prioritise more common conditions, and also that many health professionals have never seen a case before.2 Rare diseases are often difficult to diagnose, leading to the often described ‘diagnostic odyssey’3. The case has been made that even after this odyssey is concluded with a definitive diagnosis, the journey continues as people with a rare disease seek to access the best management care.4

Designers of electronic resources are urged to consult key stakeholders to enhance the effectiveness and usability of resources for people with a rare disease.
Less than 5% of the estimated 7000 rare diseases currently have an effective treatment.1 The low number of cases of each rare disease means that evidence is often lacking to guide best practice. For example, CLN12 disease with an incidence of only one per million has too few people with the disease to set up a clinical trial to test the effectiveness of potential treatments or even map the ‘typical’ progression of the disease.5 Guidance on best practice must be determined through consensus recommendations of specialists in the condition,6 7 which are often enhanced by the input of consumers who are living with the condition.8

A number of studies have explored the specific needs of people with a rare condition.3-11 Access to appropriate specialist services, finding a generalist health provider who is willing to learn about the condition, living with uncertainty of what is best practice, and the trial and error nature of discovering it have all been reported.4

Electronic resources, by which we mean mobile applications, websites, virtual monitoring devices, social media platforms, telehealth capability and online portals, hold promise of greater connectivity and collaboration in the field of rare diseases. Electronic resources are already being used to improve understandings of rare diseases as national and international online registries12 13 and virtual research consortiums14 15 pool their data and consolidate findings.

Electronic resources have a key role for people living with a rare disease. It is recognised that a useful lever to accessing the best management care for people with a rare disease is empowerment, in which people become knowledgeable about their illness and feel able to advocate for their care.16 Tools to foster empowerment are particularly relevant in this group, and electronic resources hold great promise to make information and resources more easily accessible. To our knowledge, no one has surveyed this fragmented field to determine the role of electronic resources for people with a rare disease.

This paper aims to systematically scope the peer-reviewed literature to (1) identify issues facing people with a rare disease that authors report may be addressed by electronic resources, and (2) to collate evidence around features of effective and user-friendly e-resources.

**METHODS**

We systematically searched for peer-reviewed literature on consumer-facing electronic resources for people with a rare disease, guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews17 (see online supplemental file 1 for the completed PRISMA-ScR checklist). The search was supplemented with a hand search of relevant peer-reviewed journals. Patients and public were not directly involved in the design, reporting or dissemination plan of this paper.

Three databases, Medline, Embase and PsyInfo, were searched in July 2021. No date limits were set but we only included articles in the English language. We targeted empirical peer-reviewed full articles but initial exploratory searches showed that a large proportion of the retrieved items were conference presentations on resources not reported elsewhere. These were therefore also included in the review. Search terms were developed through exploration of Medical Subject Heading terms and key words from equivalent papers from other fields. Search strings combined terms for rare disease (including specific named rare disease conditions to maximise results), with patient and carer facing resources (eg, health resources, patient participation), and terms associated with electronic resources (eg, mobile applications, cell phone, e-health). In addition, a hand search was performed in Orphanet Journal of Rare Diseases (searching for patient-focused electronic resources) and Journal of Medical Internet Research (searching for applications for rare diseases). Search strings are shown in online supplemental file 2.

The definition of a rare disease as having an incidence of less than 1:2000 was used as a guide only as the grouping together of related rare diseases muddied the waters on exact rates, as did the range of definitions employed when reporting on rare diseases. The search therefore drew on named rare conditions/groups of conditions and the most common types of rare diseases (based on research effort for therapeutic companies around the world).18 Imperfect as that list is, it retrieved many more useful articles than the generic rare disease terms. ‘Mitochondrial respiratory chain disorders’ was also added as a large group of rare diseases that are not amenable to pharmaceutical treatment. The condition groups searched for by name therefore were narcolepsy, primary biliary cholangitis, Fabry disease, cystic fibrosis, haemophilia, spinal muscular atrophy, retinal dystrophy, X-linked hypophosphatemia, urea cycle disorders, pulmonary arterial hypotension, cerebral adrenoleukodystrophy, hereditary angioedema, AA amyloidosis, Cushing’s syndrome and mitochondrial respiratory chain disorders.

The following inclusion criteria needed to be met for a paper to be included: (1) the paper was framed around the needs of people diagnosed with a rare disease or group of rare diseases (defined as incidence <1:2000); (2) the focus was on how an electronic resource could meet that need in some way; (3) either proposed and described a particular electronic resource, or reported on the development, testing or evaluation of an actual electronic resource. Exclusion criteria were as follows: (1) not about a rare disease or group of rare diseases; (2) electronic resources were not consumer-facing (eg, virtual monitoring where the consumer has a passive role and no access to the data, applications that consumers used altruistically to collect data for researchers; electronic tools for healthcare professionals only).

Search results were downloaded into reference management software EndNote V.X9 and two researchers (JCL and SB) independently screened 50% of titles and abstracts using the eligibility criteria. Disagreements
were discussed until consensus was met. Remaining articles were screened by JCL. Included articles were read in full and eligibility criteria again applied (by JCL and validated by SB). Data were extracted from the final set: rare disease/group of diseases, name of the e-resource, need identified in the patient cohort, features of the e-resource, any other findings or observations of interest.

The final step was collating and synthesising the needs of people with a rare disease discussed in the articles, looking for similarities and differences across different rare diseases and the electronic solutions proposed for each. From this, a framework was developed describing the synthesised domains of needs and examples of electronic resources designed to meet the need.

RESULTS

The search resulted in 383 papers. Title and abstract screening removed 225 papers and full text screening, another 33. This left 72 papers for data extraction and analysis. Figure 1 shows the PRISMA flow chart for the search.

Studies were set in 16 different countries including seven papers that included all of Europe. The USA (n=14), the UK (n=11) and Canada (n=10) were the best represented countries. Figure 2 shows frequencies of all countries. Twenty-one different rare diseases were represented mostly in single papers, while eight papers focused on rare diseases generally (n=8). The most common rare disease reported was cystic fibrosis (n=28) followed by haemophilia (n=19). Table 1 shows the details.

Most papers reported on e-resources that were being trialled or were under development (n=56 e-resources from 64 papers), while 12 were framed as scoping exercises or explored usability of existing websites. For example, Nicholl and colleagues explored the needs of people with rare diseases that could be met by a consumer-facing
A common problem across all the rare diseases represented in this review was access to high-quality, culturally and demographically appropriate information from a credible source that was easy to find and understand. Information sought could be around the nature of the disease, medical treatments, prognoses, etc, for the person with the disease and sometimes also for the health professionals supporting them. Links to registries and research consortia helped people stay up to date with treatment options. Information about day-to-day management issues was often sought from social networks of people with experience of the same disease rather than specialist health professionals. One paper critiqued existing online information on the rare disorder narcolepsy, following a study that showed access to high-quality web-based information could reduce time to diagnosis through better understanding of signs and symptoms. Some informational needs related to ‘niche’ topics, for example, an app for the subset of people with mild haemophilia to help them assess for cryptic bleeds after injury.

**Specialist centres for rare diseases may be geographically dispersed**

Another common problem was the small number of rare disease specialist centres that could be widely dispersed geographically. Some e-resources provided directories for the nearest specialist centre, or nearest, appropriately skilled allied health provider or patient advocacy agency. Others proved virtual consultations or tailored exercise or mental health services via telehealth.

---

**Table 2 Types of resources found, their features and their benefits**

| Type of e-resource | Features and benefits |
|--------------------|-----------------------|
| Mobile applications (apps) | Apps for phones and tablets can provide portable, always available and easily accessed information, data entry (eg, symptom trackers, guidelines, calculators) and links to other resources |
| Social networking platforms | Facilitating contact/emotional support between isolated people with the same rare disease; access to advice for day-to-day management queries |
| Telehealth and virtual care platforms | Rare disease specialists are also rare, often involving long journeys to see them face to face. Telehealth consults allow easier access. Virtual care, where patient uploaded data can be shared with a health professional, also overcomes the burden of travel and facilitates access to care from an appropriate specialist. |
| Websites (interactive) | Websites with interactive components allow the patient to enter their data and tailor content. Patient education through quizzes and games especially useful for younger people. |
| Websites (passive) | High-quality information can be made easily accessible on a website |

---

Website; Rüther and colleagues researched what people with rare liver disorders need in an app; and Aizawa and colleagues critiqued information available on the internet for people with narcolepsy.

E-Resources fell into five broad categories: (1) mobile applications (apps) for cell phones or tablets (n=22), (2) social networking platforms (n=14), (3) telehealth and virtual care platforms (n=13), (4) interactive websites (interactive content, eg, education modules with quizzes) (n=15) and (5) passive websites (passive content, eg, information) (n=7). Some e-resources fit into more than one category (eg, WhatsApp platform for parents of newly diagnosed infants with haemophilia provided social support from other parents as well as virtual consults with specialists). In these cases, the main function decided the category. Table 2 shows the types of resources, their features and their benefits.

Synthesised themes from the data extraction led to the identification of 4 domains and 23 subdomains of needs of people with a rare disease or parents of children with a rare disease. A range of unique needs arising from features of individual diseases were identified (eg, risk of life-threatening acute episodes in Addison’s disease in a context of few emergency health professionals being knowledgeable or confident to deal with adrenal crisis), as well as more global needs that were common across all presentations (eg, the scarcity of high quality, relevant information about individual rare diseases). Needs are summarised in table 3, giving examples of disease-specific needs in each subdomain and examples of the e-resources that had been developed or proposed to address those needs. Data extracted from the final set of items are given in full in online supplemental file 3.

**Chronic diseases requiring complicated self-management**

Many rare diseases were described as having a high disease burden relying on complicated self-management regimes. The association of adherence to specific treatments with better health outcomes is strongly supported by evidence for cystic fibrosis, metabolic diseases requiring medical diets and haemophilia, providing a clear rationale for supporting self-management. Optimal self-management in many cases required careful record-keeping of symptoms and tracking of treatments. Mobile apps were often designed to assist with this need. Symptom trackers were a common feature with or without medication alerts or treatment information (pancreatic enzyme replacement therapy for people with cystic fibrosis). Some had a function that allowed sharing of patient entered data with their healthcare team. Others tracked dietary intake for those on a medical diet.

**Lack of high-quality information**

A common problem across all the rare diseases represented in this review was access to high-quality, culturally and demographically appropriate information from a credible source that was easy to find and understand. Information sought could be around the nature of the disease, medical treatments, prognoses, etc, for the person with the disease and sometimes also for the health professionals supporting them. Links to registries and research consortia helped people stay up to date with treatment options. Information about day-to-day management issues was often sought from social networks of people with experience of the same disease rather than specialist health professionals. One paper critiqued existing online information on the rare disorder narcolepsy, following a study that showed access to high-quality web-based information could reduce time to diagnosis through better understanding of signs and symptoms. Some informational needs related to ‘niche’ topics, for example, an app for the subset of people with mild haemophilia to help them assess for cryptic bleeds after injury.
### Table 3  Domains and subdomains of needs of people with a rare disease that can be solved or supported by a consumer-facing electronic resource

| Domain | Subdomains with disease-specific examples | e-Resource examples |
|--------|------------------------------------------|---------------------|
| Chronic diseases requiring self-management | Complicated self-management (eg, monitoring for bleeds and factor usage for haemophilia[^49][^74]) | Online tool (Metabolic DietAppSuite) for smartphones/desktops for 15 different inborn errors of metabolism. Creates a personalised dashboard including specific nutrient goals: food diary, nutrient counts[^13] |
| | Some treatment regimes require detailed record keeping to optimise outcomes (eg, treatment of infections in CF[^33][^51][^56][^75]) | MyCBDR (linked to Canadian Bleeding Disorder Registry (CBDR)) is an app that allows people with a bleeding disorder to track infusions and add symptoms. Data can be shared with all Haemophilia Treatment Centres in Canada.[^35] |
| | Transition to self-care as adolescents become adults (eg, teens with severe haemophilia[^49][^76]–[^78]) | Smartphone app (Faccio Centro) aimed at adolescents with CF that lists daily therapy, with instructions on order, progress tracking, alerts for when to start and when checks are needed. Also can email questions to healthcare team.[^79] |
| | Exercise programmes need to be tailored to the rare disease (eg, reduced lung function and exercise tolerance in people with CF[^61][^80]–[^81]) | LAM App on smartphone with interfacing wearable devices for women with lymphangioliomyomatosis (LAM). Tailored exercise programme and physio check in.[^64] |
| | Monitoring changes in symptoms and treatments (eg, recognising bleeds in mild haemophilia[^58]–[^82]) | MyCyFAPP calculates pancreatic enzyme replacement therapy doses for fat digestion, a symptoms diary, educational material and linked to a web tool allowing health professionals to view data and give feedback.[^28][^30][^55] |
| | Burden of hospital attendance (eg, living far away from only specialist centre for narcolepsy[^63]); rare diseases with high disease burden (eg, CF[^94]) | An ultrasound diagnostic solution for children with haemophilia, the EMO.TI.ON. System used at home by parents or caregivers to diagnose suspected bleeds. System can transfer live images to specialist physician.[^35] |
| | Depression, anxiety, distress affect adherence to treatment regimes, which in turn affect health and quality of life (eg, distress of parents of newly diagnosed children with haemophilia[^77]) | Internet delivered cognitive–behavioural therapy sessions, eHealth CF-CBT guided by a qualified therapist for people with cystic fibrosis experiencing depression or anxiety[^42] |
| Lack of high-quality information on all aspects of the rare disease | Information that is readable, accessible and from a credible source (eg, lack of specific information on rare and congenital anaemias[^56]) | Newborn Screening Connect (NBS Connect) provides high-quality information for parents of children diagnosed with a disorder included in the newborn screening panel performed routinely in the USA.[^43] |
| | Information available in your language, appropriate for your culture (eg, Canadian haemophilia resources in English and French[^58]–[^75]) | Online education package for congenital hypogonadotropic hypogonadism and the ollacto-genital syndrome is available in 20 European languages. Readability score meets recommended level.[^26] |
| | Appropriate to age group or special needs (eg, information for teens with CF[^96]) | NIH.vision website on genetic eye disorders optimised for people with impaired vision[^10] |
| | Access to relevant clinical trials, or new research findings may be difficult to find[^45] | NIHR Rare Diseases Clinical Research Network (RDCRN) notifies registrants with a range of rare disorders of relevant studies[^42] |
| | Disease-specific information on niche topics like family planning (eg, for genetic disorders such as CF[^96]) | Facebook group (MyGirlsBlood) for women with bleeding disorders where women can ask questions or share experiences especially around menstruation[^34] |
| | Urgent need for disease specific information during COVID-19 pandemic[^46] | Weekly webcasts on COVID-19 for people with CF with questions through Google forms. Email notifications of webcasts sent to known patients in the USA.[^46] |
| | Specialist centres may be geographically dispersed and hard to find | Identifying appropriate care for rare disease (eg, nearest specialist; appropriately trained allied health professionals (eg, physios who know risks of exercise with haemophilia[^41])) | Mobile app developed by VASCERN (European Reference Network on Rare Multisystemic Vascular diseases) contains an easily searchable directory to find closest expert and to find appropriate patient advocacy group within Europe[^44] |

[^49]: Long JC, et al. BMJ Open 2022;12:e060394. doi:10.1136/bmjopen-2021-060394
Social isolation from peers and advice networks
The social isolation that comes from having a rare disease is often discussed as a need unique to people with a rare disease. Khair and colleagues noted that for many adolescent boys with haemophilia, the only person other than their doctor who knows about their disease is their parent. Limited access to specialist services means people or parents of a child with a rare condition have to face non-urgent day-to-day issues by themselves unless they find appropriate social support. Social support could be with people with the same disease (eg, Facebook/Twitter group for Hirschsprung’s disease) or include health professionals (eg, online support group for thoracic outlet syndrome).

DISCUSSION
This review found 72 papers outlining the needs of people with a rare disease, or their carers that could be addressed by an e-resource. Four domains and 23 subdomains of needs were identified and e-resources to address or support those needs were broadly categorised into five groups: mobile apps, social support platforms, telehealth and virtual health tools, and interactive and passive websites.

A range of unique needs arising from features of individual diseases were identified. Examples included the burden of constant physical isolation to prevent infection for people with cystic fibrosis, the acute distress of parents of infants with osteogenesis imperfecta at suspicions of child abuse that often preceded diagnosis and the difficulty of recognising signs of an impending adrenal crisis for people with Addison’s disease that can be life threatening.

While the burden of disease for rare disorders may be similar to higher incidence conditions such as stroke or breast cancer, the added burden of the lack of a solid evidence base of effective treatments, best practice guidelines and competent and knowledgeable health service providers is not. The well-documented
diagnostic odyssey for people with rare diseases and laments that health professionals had never heard of their disease is a burden unique to this group.

This burden of uniqueness spills over to other needs. Exercise is crucial for physical and mental well-being but for many people with a rare disease, any exercise programme must be tailored and supervised by a suitably knowledgeable health professional. Reduced exercise tolerance for people with cystic fibrosis and LAM, and risk of bleeds into their joints for people with haemophilia were addressed by telehealth or online modules. Social support of group exercise classes is known to alleviate psychological distress and anxiety and carers, on whom the burden of management often falls. The distress that parents feel on diagnosis of a child with a rare disease was frequently discussed (mostly parents). The distress that parents feel on diagnosis of a child with a rare disease was frequently discussed and provided the rationale for social support platforms and found them to be overwhelmingly positive and supportive. Real-time, knowledgeable solutions to problems, plus emotional support, were demonstrated as highly valuable to members and these benefits were noted as important goals for any proposed new e-resources.

It has been argued that an often overlooked need for people with a rare disease is support for their parents or carers, on whom the burden of management often falls. This review identified 15 e-resources that supported carers (mostly parents). The distress that parents feel on diagnosis of a child with a rare disease was frequently discussed and provided the rationale for social support platforms and messaging apps, management support apps and telehealth tools. One German study provided parents of children with cystic fibrosis online writing-based therapy to alleviate psychological distress and anxiety.

Readability of information found on the internet has been widely critiqued and criticised. A typical example is a review of online education resources from government and healthcare organisations on multiple sclerosis and rheumatoid arthritis (neither considered rare diseases) were found to be written at 11th or 12th grade standard, whereas the average American reads at a 5th grade standard. The authors state material that is too complex limits its usefulness and increases inequities. E-resources in this review were often noted to be co-designed by health professionals, patient advocacy agencies, parents and people with a rare disease, as well as education experts, to mitigate this risk. Usability and acceptability studies were reported for some but not all the resources found in this review. Ensuring resources are easy to understand, appeal to the target group’s demographics (eg, adolescents vs older adults) and suited to the skills of the users is an obvious goal but one that this scoping review did not always find was done well. Patient advocacy agencies are noted in the broader literature to be particularly proactive in ensuring acceptable and easy to understand resources. A survey of patient advocacy groups for people with rare diseases found 100% of respondents would be interested in collaborating with relevant healthcare or research groups to develop complementary resources suited to their members, and avoid wasted effort involved in duplication.

The very low incidence of rare diseases mean that patients and appropriate services are geographically widely distributed. Electronic resources such as telehealth, social networking platforms and specialised apps are therefore ideal solutions to provide appropriate care. Progress in understanding diseases that are rare has been accelerated in recent years as clinicians and scientists around the world pool the data they have on local. A similar benefit comes for patients as they find or are linked to others with knowledge and experience of their unique situation. Currently, the efficacy of e-resources for people with a rare disease is being realised one disease group at a time. While each disease has its unique features, we have shown here that the needs of all people with rare disease are basically the same. These domains of needs should be addressed by any team wishing to develop new e-resources for this cohort.

**Strengths and limitations**

The nature of the topic (e-resources) lent itself more to conference presentations rather than full peer-reviewed articles. A strength of our search was that we included these items, although a weakness is that limited information was able to be extracted from some abstracts. Further, there was likely an element of publication bias where only successfully developed e-resources were reported. The main limitation to our review was the difficulty capturing articles focused on people with a rare disease. Our search was systematic but does not claim to be exhaustive. In particular, the search terms to capture rare diseases were problematic. Since there are over 7000 rare diseases, it was not feasible to search for each by name. Our strategy was therefore to search for a limited number of named rare disease groups. The lists of needs identified are characteristic of any rare disease, and while some needs are unique to some specific disease manifestation, the majority were applicable to all. This generalisability will be useful for anyone designing e-resources to support people with a rare disease.

**CONCLUSION**

This review scoped the peer-reviewed literature to identify needs unique to people, or carers of people with a rare disease. It identified four broad domains of need: (1) support for complicated self-management regimes, (2) access to high-quality, easy to understand information, (3) access to appropriate specialist services and (4)
social support. Most studies involved needs of people or caregivers of children with haemophilia or cystic fibrosis but also addressed another 20 named rare diseases or rare disease groups (eg, inborn errors of metabolism). While the physical burden of a rare disease may be comparable to higher prevalence conditions such as stroke or cancer, rare diseases have unique overlying issues: the lengthy odyssey to find a diagnosis, the quest to find appropriate specialists to manage your care, the lack of a solid evidence base of effective treatments or best practice guidelines, or access to competent and knowledge- able general health service providers are unique to those with a rare disease. e-Resources are well placed to address many of these problems but must be carefully co-designed with key stakeholders lest their complexity, narrow scope or cultural inappropriateness further disempower this already marginalised group.

Twitter Janet C Long @JanetCLong

Acknowledgements The research conducted at the Murdoch Children’s Research Institute was supported by the Victorian Government’s Operational Infrastructure Support Program. The Chair in Genomic Medicine awarded to JC is generously supported by The Royal Children’s Hospital Foundation.

Contributors JCL, SB, SH and BNGE designed the study. JCL and SB collected data and undertook the analysis. SH, ZF, BNGE, JC and JB critically reviewed and commented on the results. JCL wrote the first draft of the paper which was reviewed by SB, SH, ZF, BNGE, JC and JB. All authors approved the final version. JCL acts as guarantor for this study.

Funding This project was funded by a Milto Foundation Project Grant 2019-21.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study. All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Janet C Long http://orcid.org/0000-0002-0553-682X
Bróna Nic Giolla Easpaig http://orcid.org/0000-0001-6787-056X
Jeffrey Brathwaite http://orcid.org/0000-0003-0296-4957

REFERENCES
1 Boycott KM, Vanstone MF, Bulman DE, et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 2013;14:681–91.
2 Ramalle-Gómez E, Dominguez-Gamido E, Gómez-Eguilaz M, et al. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis 2020;15:18.
3 Thevenon J, Duffourd Y, Masurel-Paulet A, et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin Genet 2016;89:700–7.
4 Long JC, Best S, Hatem S, et al. The long and winding road: perspectives of people and parents of children with mitochondrial conditions negotiating management after diagnosis. Orphanet J Rare Dis 2021;16:310.
5 Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol 2013;28:1142–50.
6 Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the mitochondrial medicine Society. Genet Med 2015;17:869–701.
7 Ghebrhiwot T, Morgan LA. Patient and public involvement in the development of healthcare guidelines for rare diseases (rare disease patients and/or the public). Orphanet J Rare Dis 2018;13:50.
8 Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases Research. Orphanet J Rare Dis 2018;13:196.
9 Depping MK, Uhlenbusch N, von Kolditzsch Y, et al. Supportive care needs of patients with rare chronic diseases: multi-method, cross-sectional study. Orphanet J Rare Dis 2016;11:44.
10 Kreuter M, Benestrup C, Russell A-M, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med 2017;5:968–80.
11 Quinn L, Davis K, Yee A, et al. Understanding genetic learning needs of people affected by rare disease. J Genet Couns 2020;29:1050–8.
12 Rubio-Gozalbo ME, Haskovic M, Bosch AM, et al. The natural history of classic galactosaemia: lessons from the GalNet registry. Orphanet J Rare Dis 2019;14:86.
13 Scalco RS, Lucia A, Santalla A, et al. Data from the European Registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC), Orphanet J Rare Dis 2020;15:330.
14 Woodward L, Johnson S, Walle JV, et al. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the global aHUS Registry. Orphanet J Rare Dis 2016;11:154.
15 Pavan S, Rommel K, Mateo Marquina ME, et al. Clinical practice guidelines for rare diseases: the Orphanet database. PLoS One 2017;12:e0170365.
16 Le Cam Y, Bolz-Johnson M. Expert by experience: Valuing patient engagement in healthcare. In: Pomey M-P, Denis J-L, Durnez V, eds. Patient engagement: how patient-provider partnerships transform healthcare organisations. Cham, Switzerland: Palgrave Macmillan, 2019: 233–67.
17 Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169:467–73.
18 Ghosh I. Infographic: which rare diseases are the most common? : Visual Capitalist, 2019. Available: https://www.visualcapitalist.com/ which-rare-diseases-are-the-most-common/
19 Nicholl H, Tracey C, Begley T, et al. Internet use by parents of children with rare conditions: findings from a study on parents’ web information needs. J Med Internet Res 2017;19:e61.
20 Rüther DF, Sebode M, Lohse AW, et al. Mobile APP requirements for patients with rare liver diseases: a single center survey for the ERN RARE-LIVER ... Clin Res Hepatol Gastroenterol 2021;45:101760.
21 Aizawa R, Sunahara H, Kume K, et al. Diagnostic and management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis 2018;13:50.
22 Rüther DF, Sebode M, Lohse AW, et al. Mobile APP requirements for patients with rare liver diseases: a single center survey for the ERN RARE-LIVER ... Clin Res Hepatol Gastroenterol 2021;45:101760.
23 Colman AW, Sellick JFK, Weaver JU. Use of Quick Response (QR) coded bracelets and cards for the improvement of cortisol deficiency/Addison’s disease management: an audit of quality of care of the management of steroid deficiency in acute illness. BMJ Innovations 2018;4:115–22.
24 Ackbarali T, Croteau SE, Pipe SW, et al. Assessing patient and provider perspectives, clinical practice, behaviors, and knowledge on hemophilia a care. Blood 2020;136:24–5.
25 et al. Armayones M, Hernandez-Encuentra E, Gomez-Zuniga B. APTIC: a social network to improve the quality of life of members of patients’ associations. Orphanet Journal of Rare Diseases
Conference: 5th European Conference on Rare Diseases, ECRD, 2010.

26 COST Action BM1105, Badiu C, Bonomi M, et al. Developing and evaluating rare disease educational materials co-created by expert clinicians and their patients: the paradigm of congenital hypogonadotropic hypogonadism. *Orphanet J Rare Dis* 2017;12:57.

27 Barazani Bruntman T, Bashari D, Lenda H. New communication technologies improve hemophilia care. *Haemophilia* 2017;23:134–5.

28 Boon M, Calvo-Lerma J, Claes I, et al. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastrointestinal related quality of life in children with cystic fibrosis. *J Cyst Fibros* 2020;19:562–8.

29 Breakey VR, Ignasz DM, Warias AV, et al. A pilot randomized control trial to evaluate the feasibility of an Internet-based self-management and transitional care program for youth with haemophilia. *Haemophilia* 2014;20:784–93.

30 Calvo-Lerma J, Boon M, Hulst J, et al. Change in nutrient and dietary intake in European children with cystic fibrosis after a 6-month intervention with a self-management eHealth tool. *Nutrients* 2021;13:1801.

31 Castro AR, Chougkhi K, Bilodeau C, et al. Exploring the views of osteogenesis imperfecta caregivers on Internet-based technologies: qualitative descriptive study. *J Med Internet Res* 2019;21:e15824.

32 Cipriani D, Dufian E. See and be seen: the CF community. *Pediatrie Pulmonol* 2017:147–8.

33 Cummings E, Hauser J, Cameron-Tucker H, et al. Enhancing self-efficacy for self-management in people with cystic fibrosis. *Stud Health Technol Inform* 2011;169:33–7.

34 D’Ambrosio C. Open versus closed social networking groups. *Haemophilia* 2014:183.

35 Decker K, Meilleur C, CBDR and MyCBDR advancing hemophilia nursing practice in Canada. *Haemophilia* 2018:37.

36 Haik D, Kanschani K, Tajarani S, et al. The online support group as a community: a thematic content analysis of an online support group for idiopathic subglottic stenosis. *Ann Otol Rhino Laryngol* 2019;128:293–9.

37 Kauw D, Repping-efues H, Noordzij A, et al. The contribution of online peer-to-peer communication among patients with adrenal disease to patient-centered care. *J Med Internet Res* 2015;17:e54.

38 Kirk S, Milnes L. An exploration of how young people and parents use online support in the context of living with cystic fibrosis. *Health Expect* 2016;19:309–21.

39 Kühnle L, Mücke U, Lechner WM, et al. Development of a social network for people without a diagnosis (RarePairs): evaluation study. *J Med Internet Res* 2020;22:e1849.

40 Yeong JI, Thomas P, Buller J, et al. A newly developed web-based resource on genetic eye disorders for users with visual impairment (Gene.Vision): usability study. *J Med Internet Res* 2021;23:e19151.

41 Manu-Pereira MM, Gutierrez-Valle V, Vives-Corrons JL. ENERCA: towards a European reference network (ERN) in rare haematological diseases. *British Journal of Haematology* 2016:39–40.

42 Moon H, Moon J. Comparative readability analysis of information on exercise for hemophilia patients. *Haemophilia* 2021;27:57.

43 Osara Y, Corredor Corrales M, Salinas Coll, et al. Development of a newborn screening connect (Nbs connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders. *Orphanet J Rare Dis* 2017;12:132.

44 Pagliaongia A, Gaitano R, Robert L, et al. eHealth for patients with rare diseases: the eHealth Working group of the European reference network on rare multisystemic vascular diseases (VASCERN). *Orphanet J Rare Dis* 2021;16:164.

45 Richesson RL, Lee HS, Cuthbertson D, et al. An automated communication system in a contact Registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants. *Contemp Clin Trials* 2009;30:55–62.

46 Rits S, Snell C, Uluer AZ. Weekly patient webcasts: An adult CF center's response to the COVID-19 pandemic. *Pediatric Pulmonology* 2020:78.

47 Rodman J, Krivec U, Jackson A, W523.6 patient perspectives on electronic access to registry health records: an Irish-Slovene online survey. *Journal of Cystic Fibrosis* 2016;15:S56.

48 Storf H, Hartz T, Tegtbaue N. Vision and challenges of a cartographic representation of expert medical centres for rare diseases. *Stud Health Technol Inform* 2014;205:677–81.

49 Walker KX. Cognitive and affective uses of a thoracic outlet syndrome Facebook support group. *Health Commun* 2014;29:773–81.

50 Wittmeier K, Holland C, Hobbs-Murison K, et al. Analysis of a parent-initiated social media campaign for Hirschsprung’s disease. *J Med Internet Res* 2014;16:e288.

51 Wood J, Jenkins S, Putrino D, et al. A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of exacerbations: results of a randomised controlled trial. *J Cyst Fibros* 2020;19:271–6.

52 Sanders DB, Bittner RCL, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. *Am J Respir Crit Care Med* 2010;182:627–32.

53 Cipriano LE, Rupar CA, Zarcí GS. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. *Value Health* 2007;10:83–97.

54 Nilsson IM, Bertorp E, Löfqvist T, et al. Twenty-Five years’ experience of prophylactic treatment in severe haemophilia A and B. *J Intern Med* 1992:232:25–32.

55 Calvo-Lerma J, Boon M, Colombo C, et al. Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis. *J Cyst Fibros* 2021;20:e33-e39.

56 Flöch J, Vlairinho T, Zetti A, et al. Users’ experiences of a mobile health self-management approach for the treatment of cystic fibrosis: mixed methods study. *JMIR Mhealth Uhealth* 2020:e81586.

57 Howard S, Speight L, Mills-Bennett R, et al. WS9.6 the all Wales adult cystic fibrosis centre (AWACFC) virtual instruction of exercise with technology to enhance care – VIEWTEC programme. *Journal of Cystic Fibrosis* 2014:13:320.

58 Lomotey RK, Mulder K, Nilson J, et al. Mobile self-management guide for young men with mild hemophilia in cases of minor injuries. *Network Modeling Analyses in Health Informatics and Bioinformatics* 2016:13.

59 Manu-Pereira MM, Gutierrez-Valle V, Vives-Corrons JL. ENERCA: towards a European reference network (ERN) in rare haematological diseases. *British Journal of Haematology* 2016:173:39–40.

60 Sottiglotta G, Amigo P, Drago L. The HEMONLINE project: preliminary results. *Slovene Haemophilia Journal* 2017.

61 Carr SB, Ronan P, Lorenz A, et al. Children and adults tai chi study (CF-CATS2): a randomised controlled feasibility study comparing internet-delivered with face-to-face tai chi lessons in cystic fibrosis. *ERU Open Res* 2018;4:00042-2018.

62 Verklek M, Gargioli I, Friedman D. Development and evaluation of an Internet-based cognitive behavioral therapy intervention for anxiety and depression in adults with cystic fibrosis (eHealth CF-CBT): an international collaboration. *Internet Interv* 2016;19:100372.

63 Khair K, Holland M, Carrington S. Social networking for adolescents with haemophilia. *Haemophilia* 2011:369.

64 Guilliams JM, Garvin M, Sizelove H. Feasibility and usefulness of a mobile health exercise intervention in women with lypmphangioliomyomatosis. *Cardiopulmonary Physical Therapy Journal* 2013;4.

65 Cox NS, Eldridge B, Rawlings S, et al. A web-based intervention to promote physical activity in adolescents and young adults with cystic fibrosis: protocol for a randomized controlled trial. *BMJ Pulm Med* 2019:19:253.

66 Lewis T. Improving quality of life in patients with cystic fibrosis with exercise: CF Foundation impact grant update. *Pediatric Pulmonology* 2019;385–6.

67 Wagner B, Seuser A, Krüger S, et al. Establishing an online physical exercise program for people with hemophilia. *Wien Klin Wochenschr* 2019;131:558–66.

68 Foronda CL, Kelley CN, Nadeau C, et al. Psychological and socioeconomic burdens faced by family caregivers of children with asthma: an integrative review. *J Pediatr Health Care* 2020;34:366–76.

69 Suárez-Lledó I, Alvarez-Galvez J. Prevalence of health misinformation on social media: systematic review. *J Med Internet Res* 2021;23:e17187.

70 McMullan J, Crowe AL, Ballie C, et al. Improvements needed to support people living and working with a rare disease in Northern Ireland: current rare disease support perceived as inadequate. *Orphanet J Rare Dis* 2020;15:315.

71 Fidika A, Herle M, Lehmann C, et al. A web-based psychological support program for caregivers of children with cystic fibrosis: a pilot study. *Health Qual Life Outcomes* 2015:13:11.

72 Linton L, Aruru M. Evaluating the readability of patient education materials across multiple sclerosis and rheumatoid arthritis disease states. *J Am Pharm Assoc* 2013;53:e28.

73 Ho G, Ueda K, Houben RFA, et al. Metabolic diet APP suite for inborn errors of amino acid metabolism. *Mol Genet Metab* 2016;117:322–7.

74 Huang X, Chen L, Shao S. Developing and evaluating HE-APP: acceptability and usability of a smartphone APP system to improve...
self-management in Chinese patients with hemophilia. *Haemophilia* 2020:99.

75 Grande SW, Kotzbauer G, Hager A. Improving care for pediatric cystic fibrosis in Sweden using a successful mHealth patient support system. *Pediatric Pulmonology* 2017:435.

76 Breakey VR, Warias A, Ignas DM, et al. Usability testing of an online transition program for adolescents with hemophilia. *Haemophilia* 2012:31.

77 Khair K, Collier C, Holland M. The role of social networking in haemophilia management. *Haemophilia* 2010:129–30.

78 Khair K, Holland M, Carrington S. Social networking for adolescents with severe haemophilia. *Haemophilia* 2012:18:e290–6.

79 Balestri E, Vergnani S, Dall’Ara S. ‘F (accio) C (entro)’: Project for a smartphone application to increase adherence to aerosol treatment in adolescents with cystic fibrosis. *Italian Journal of Pediatrics Conference: 25th Italian Congress of Cystic Fibrosis and the 15th National Congress of Cystic Fibrosis Italian Society Milan Italy*, 2020.

80 Cox NS, Alison JA, Button BM, et al. Feasibility and acceptability of an Internet-based program to promote physical activity in adults with cystic fibrosis. *Respir Care* 2015;60:422–9.

81 Howard S, Speight L, Mills-Bennett R, et al. WS9.6 the all Wales adult cystic fibrosis centre (AWACFC) virtual instruction of exercise – VIEWTEC programme. *J Cystic Fibrosis* 2014:13:S20.

82 Nilson J, Mulder K, Schachter C. Development, evaluation and updates of Hirt? (hemophilia injury recognition tool). *Haemophilia* 2018:136.

83 Ingravallo F, Vignatelli L, Pagotto U. Telemedicine with mobile Internet devices for innovative multidisciplinary patient-centred care of patients with narcolepsy. protocol of the randomized controlled trial TENAR (telemedicine for narcolepsy). *Euro J Neurol* 2020:516.

84 Parrott H, Elborn S, Madge S. ePS5.04 a digital solution for virtual consultation and sharing health data in adults with cystic fibrosis. *Journal of Cystic Fibrosis* 2019:18:S51.

85 Lassandro G, Annichiarico G, Scherillo MR. EMO.TI.ON.: technologies for the safety of children with hemophilia. *Blood Transfusion* 2017:s539.

86 Rudolf I, Pieker P, Nolte H, et al. Assessment of a mobile APP by adolescents and young adults with cystic fibrosis: pilot evaluation. *JMIR Mhealth Uhealth* 2019;7:e12442.

87 Timmer MA, Kloeck CJJ, de Kleijn P, et al. A blended physiotherapy intervention for persons with hemophilic arthropathy: development study. *J Med Internet Res* 2020;22:e16631.

88 Sottilotta G, Arigo P, Drago L. The HEMONLINE project: preliminary results. *Haemophilia* 2012:77.

89 Won AS, Barreau AC, Gaertner M, et al. Assessing the feasibility of an open-source virtual reality mirror visual feedback module for complex regional pain syndrome: pilot usability study. *J Med Internet Res* 2021;23:e16536.

90 Naik H, Balwani M, Doheny D. Experience with a pilot skype Internet support group for symptomatic patients with acute intermittent porphyria. *Clinical Chemistry and Laboratory Medicine* 2013:eA10.

91 Blackwell LS, Romero SL, Romero CV. CFone: a social networking site for adolescents and young adults with CF. *Pediatric Pulmonology* 2012:430.